J Korean Med Sci.  2018 Dec;33(53):e342. 10.3346/jkms.2018.33.e342.

Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer

Affiliations
  • 1Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ccm9607@gmail.com
  • 2Health Promotion Center, Asan Medical Center, Seoul, Korea.
  • 3Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun, Korea.
  • 4Aptamer Sciences Inc., Pohang, Korea.
  • 5Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Abstract

We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, AptoDetect™-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign nodule controls, 200 participants were enrolled. In a high-risk population corresponding to ≥ 55 years of age and ≥ 30 pack-years, the diagnostic performance was improved, showing 73.3% sensitivity and 90.5% specificity with an area under the curve of 0.88. AptoDetect™-Lung (Aptamer Sciences Inc.) offers the best validated performance to discriminate NSCLC from benign nodule controls in a high-risk population and could play a complementary role in lung cancer screening.

Keyword

Aptamer; Lung Cancer Screening; Lung Nodule; Computed Tomography

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Gyeongsangbuk-do
Humans
Lung Neoplasms
Mass Screening
Sensitivity and Specificity
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr